Subscribe today to receive our latest blogs, articles, podcasts and more.
Blogs
Sharing perspectives leads to greater understanding and fuels innovation.
The Optum Insights blog is where we share our perspective and challenge preconceptions to clear a new path forward.
|
September 07, 2022 · Public Policy & Regulatory Affairs Team
Brief updates on several recent policy developments across the country. Read more... |
|
|
August 17, 2022 · Public Policy & Regulatory Affairs Team
Read more... |
|
August 11, 2022 · OWCA
This spring, Optum welcomed Jeannine Foster as our newest CEO Read more... |
|
|
July 28, 2022 · Public Policy & Regulatory Affairs Team
Read more... |
|
July 14, 2022 · Clinical Team
Effective June 30, 2022, Zelnorm 6 mg tablet will no longer be produced and marketed in the United States, as announced by its manufacturer, Alfasigma USA, Inc. Read more... |
|
July 06, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved Quviviq (daridorexant) 25 mg and 50 mg tablets on January 10, 2022. Manufactured by Idorsia Pharmaceuticals US Inc., this sedative/hypnotic is indicated for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Read more... |
|
June 24, 2022 · Medicare Insights Team
On June 6, 2022, the Supreme Court ruled 7-2 in Gallardo v. Marstiller that Florida Medicaid was permitted reimbursement from a settlement involving a permanently disabled woman. The woman, Ms. Gallardo, was involved in a catastrophic injury when she was hit by a truck while exiting a school bus. Florida Medicaid previously paid $862,688.77 in medical expenses and was expected to continue paying for future medical expenses related to this incident. Read more... |
|
June 23, 2022 · Public Policy & Regulatory Affairs Team
Read more... |
Page 1 of 19
